Navigation Links
Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2011 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting
Date:3/22/2011

IV was administered within 24 hours before a procedure.  The results cited on the poster included the following:

  • Forty-one unique subjects (8 children, 33 adults) received Cinryze for 91 procedures (40 in children, 51 in adults);
  • Approximately 55 percent of procedures involved dental work and 37 percent involved surgeries or interventional diagnostic procedures.  Among the 8 children (aged 6-17 years), 90 percent of procedures involved dental work;
  • Pre-procedural administration of Cinryze prevented HAE attacks during or following 98 percent of medical, dental, or surgical procedures;
  • Only 2 HAE attacks were reported within 72 hours after dosing: 1 genitourinary attack after dental work and 1 laryngeal attack after laparoscopy. Both resolved after treatment with an additional dose of Cinryze;
  • Seven subjects reported adverse events within 7 days after receiving Cinryze; none were considered related to Cinryze by the investigator.  

In a poster entitled, 'Safety and Efficacy of Nanofiltered C1 Esterase Inhibitor (human) (Cinryze®) for the Treatment of Laryngeal Attacks in Subjects with Hereditary Angioedema (HAE),' Dr. Marc Riedl, M.D., of the University of California, Los Angeles, David Geffen School of Medicine presented the experience of 85 subjects who received Cinryze to treat 267 laryngeal attacks of HAE.  These data were compiled from all completed studies with Cinryze.  These subjects received Cinryze 1000U IV for HAE attacks; a second 1000U dose could be administered 1 hour later if necessary. The results cited on the poster included the following:

  • Across all studies, 85 unique subjects (74 adults, 11 children) received Cinryze for treatment of 267 laryngeal attacks; of them, only 1 subject required intubation;
  • Four subjects reported SAEs that were not HAE manifestations; none were consid
    '/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union
2. Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO)
3. ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
4. ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
5. ViroPharma Files Prior Approval Supplement (PAS) for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Manufacturing
6. Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care
7. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
8. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
9. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
10. iTherX Initiates Phase 1b Study of First-in-Class Hepatitis C Virus Entry Inhibitor ITX-5061
11. N30 Pharmaceuticals to Present S-Nitrosoglutathione Reductase Inhibitor Preclinical Safety Data at 2011 Society of Toxicology 50th Anniversary Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... patent application concerning composition of matter, biological targets, mechanism ... cell death.  This patent application describes ... RNA molecules (VSRNAs) which interfere with the basic homeostatic ... size less than 10 bps, yet are surprisingly capable ...
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence ... a Medical Fitness Center by the Medical Fitness ... and fitness centers to achieve their full potential. ... only certified fitness center in the western suburbs ... "The certification means the Cadence Fitness & Health ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... market research report is available in its ... Market & Forecast – Worldwide Analysis ... Insulin Pump Market Analysis ... in the market as insulin delivery systems ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... data,supporting the clinical development of telaprevir (VX-950), one ... the,treatment of hepatitis C virus (HCV) infection, will ... European Association for the,Study of the Liver (EASL) ... to telaprevir have been accepted for presentation,at the ...
... meeting of the European,Association for the Study of ... /PRNewswire-FirstCall/ --,Schering-Plough Corporation reaffirms its commitment to advancing,the ... (HCV),infection with several key data presentations at the ... 42nd annual meeting,in Barcelona, Spain, April 11-15. A ...
Cached Medicine Technology:Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 2Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 3Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 4Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 5Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 6Schering-Plough Addresses Major Milestones and Challenges in,Treatment of Patients With Chronic Hepatitis C 2Schering-Plough Addresses Major Milestones and Challenges in,Treatment of Patients With Chronic Hepatitis C 3Schering-Plough Addresses Major Milestones and Challenges in,Treatment of Patients With Chronic Hepatitis C 4Schering-Plough Addresses Major Milestones and Challenges in,Treatment of Patients With Chronic Hepatitis C 5Schering-Plough Addresses Major Milestones and Challenges in,Treatment of Patients With Chronic Hepatitis C 6Schering-Plough Addresses Major Milestones and Challenges in,Treatment of Patients With Chronic Hepatitis C 7
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... RESULTS, EUR,000,000 2008 ... 92.5 99.3 EBITDA* ... 14.0% 16.1% Current operating income* ... (2.8) (2.7) Net income ...
... central nervous system , , WEDNESDAY, July 30 (HealthDay News) ... depression, at least in mice. , According to the ... Istvan Mody, both of the David Geffen School of ... of a particular class of proteins called GABA receptors ...
... Data from 260 hospitals across the United States has ... to more accurately determine the severity of heart failure in ... mortality and more quickly identifying triage methods and treatment decisions. ... the Journal of the American College of Cardiology . ...
... for Universal, Health Coverage Proposal but Obstacles Remain, According ... ... 30 ,HealthLeaders-InterStudy, a leading provider of managed care market,intelligence, reports ... windfall for the state of New Mexico has resulted in ...
... recently,submitted its bid to the U.S. Department of ... third generation TRICARE South Region contract. If,awarded the ... active,duty, retired and participating reserve and National Guard ... on April 1, 2010., "It is TriServ,s ...
... Sunrise Senior Living,Inc. (NYSE: SRZ ) today ... and webcast to discuss the Company,s 2007 financial ... data.,The call will now be held on Friday, ... will issue its 2007 financial results and second-quarter ...
Cached Medicine News:Health News:PCAS : Half Result 2008 2Health News:Possible Cause of Postpartum Depression Pinpointed 2Health News:Possible Cause of Postpartum Depression Pinpointed 3Health News:New method assesses risks for heart failure patients 2Health News:Gov. Richardson's Healthcare Reform Agenda Gains New Life 2Health News:Sunrise Updates Date and Time of Conference Call to Discuss 2007 Financial Results and Second-Quarter 2008 Preliminary Selected Financial and Operating Data 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: